An update from ALX Oncology Holdings ( (ALXO) ) is now available.
ALX Oncology announced notable progress in its clinical trials, showcasing promising results for its lead candidate, evorpacept, in combination therapies for cancer treatment. The company reported a significant tumor response in HER2-positive gastric cancer patients and initiated new trials for multiple myeloma. Financially, ALX reported a decreased net loss in Q3 2024 compared to the previous year, with reduced R&D and G&A expenses, bolstered by a strong cash position expected to support operations into 2026.
Learn more about ALXO stock on TipRanks’ Stock Analysis page.
